“We’re building a strong scientific base for KSM-66 as a clinically-tested adaptogen,” said Ixoreal Biomed director Kartikeya Baldwa.
Ixoreal Biomed (Hyderabad, India) plans to increase North American demand for ashwagandha (Withania somnifera) by increasing the supporting science behind its KSM-66 advanced-form ashwagandha.
Acknowledging that the North American ashwagandha market is “largely undeveloped,” Ixoreal Biomed says it is starting to publish its studies on KSM-66 on human health factors including energy, infertility, immunity, and longevity. The first of five studies Ixoreal Biomed has conducted is now published in the Indian Journal of Psychiatry. It is a human clinical trial on 64 adults under stress conditions.
“We’re building a strong scientific base for KSM-66 as a clinically-tested adaptogen,” said Ixoreal Biomed director Kartikeya Baldwa. “Even though this application had been known through traditional use, very few studies had been conducted prior to our work with KSM-66. We’ve committed our company to be the leader in ashwagandha scientific data.”
KSM-66 is a GRAS-affirmed and Halal-certified ashwagandha ingredient.